MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds received from
sale of series d...
$2,560,981
Proceeds from sale of
equity securities
$500,000
Proceeds from share
purchases and collection...
$1,278,217
Net cash provided by
financing activities
$1,424,513
Net cash provided by
investing activities
$500,000
Canceled cashflow
$2,414,685
Net increase
(decrease) in cash,...
-$1,280,602
Canceled cashflow
$1,924,513
Accounts
payable-Successor
$864,545
Write off of deferred
offering costs
$500,000
Write off of deferred
offering...
$500,000
Stock-based
compensation-Successor
$348,116
Depreciation expense
$215,069
Amortization of right-to-use
operating lease...
$203,412
Depreciation
expense-Successor
$69,354
Proceeds received from
sale of series c...
-$2,240,180
Payment of deferred
offering costs
$174,505
Net cash used in
operating activities
-$3,205,115
Canceled cashflow
$2,700,496
Net loss-Successor
-$4,856,395
something is missing
-$715,069
Operating lease
liability-Successor
-$221,595
Prepaid expenses and
other current...
$87,935
Accrued
liabilities-Successor
-$24,369
Foreign currency
transaction gain included in...
$248
Net Income Loss
-$4,856,395
Back
Back
Cash Flow
source: myfinsight.com
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)
CERO THERAPEUTICS HOLDINGS, INC. (CEROW)